

## SUPPLEMENTARY DATA

**Table S1:** Demographic data of patients (with valproic acid monotherapy) in the hepatotoxicity and control groups

Demographic characteristics	Cases	Control	<i>P</i> value
Number of patients	36 (32.1 %)	76 (67.9 %)	N/A
Age (yrs)	5.04 ± 3.28	4.66 ± 2.88	0.521
Height (cm)	109.00 ± 37.26	102.58 ± 25.18	0.353
Body weight (kg)	25.14 ± 9.92	21.42 ± 10.01	0.068
BMI (kg/m <sup>2</sup> )	20.25 ± 5.51	19.60 ± 6.73	0.617
TP (g/L)	68.56 ± 8.08	66.89 ± 5.17	0.262
ALB (g/L)	42.54 ± 8.73	42.73 ± 3.71	0.897
TBiL (μmol/L)	9.35 ± 6.88	6.84 ± 2.48	0.040
GGT (U/L)	47.58 ± 37.45	17.92 ± 13.69	<0.001
ALP (U/L)	188.28 ± 131.26	185.95 ± 59.95	0.920
ALT (U/L)	85.00 ± 45.27	12.82 ± 7.09	<0.001
AST (U/L)	98.97 ± 67.48	25.49 ± 6.60	<0.001
GSH (μmol/L)	33.52 ± 4.46	48.10 ± 3.76	<0.001
TBARS (μmol/L)	2.31 ± 0.44	2.07 ± 0.36	0.006

The bolded data indicated *P* < 0.05

**Table S2:** Comparison of serum trace elements in hepatotoxicity and control groups (with valproic acid monotherapy)

Trace elements	Cases (n = 36)	Control (n = 76)	<i>P</i> value
Co (ng/mL)	0.66 ± 0.12	0.72 ± 0.13	0.041
Cr (ng/mL)	1.58 ± 0.45	1.69 ± 0.54	0.275
Cu (μg/mL)	1.26 ± 0.21	1.25 ± 0.17	0.722
Fe (μg/mL)	1.25 ± 0.13	1.16 ± 0.12	<0.001
Mn (ng/mL)	1.95 ± 0.35	1.93 ± 0.26	0.842
Mo (ng/mL)	1.56 ± 0.23	1.62 ± 0.18	0.185
Se (ng/mL)	96.89 ± 11.17	106.92 ± 10.31	<0.001
Sr (ng/mL)	38.61 ± 10.53	40.03 ± 8.91	0.457
Zn (μg/mL)	0.84 ± 0.10	0.87 ± 0.12	0.180

The bolded data indicated *P* < 0.05